Decision-analytic Markov modeling reveals superior net monetary benefit for mosunetuzumab over CAR-T in relapsed follicular lymphoma, indicating a cost-effective alternative for payers.
T cell redirecting therapies, including mosunetuzumab (mosun), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel), are FDA-approved for relapsed refractory follicular lymphoma (FL) in the 3rd line and beyond. There's no head-to-head clinical trial data to compare their effectiveness. These products differ in administration, hospitalization requirements, and toxicity profiles, impacting therapy selection. We developed a Markov model spanning one to 10 years from a US payer perspective, using parameters from clinical trials, quality utilities, and billing costs. Our base case analysis over 10 years showed that mosun provided $67,654 more Net Monetary Benefit (NMB) per patient than axi-cel and $111,709 more than tisa-cel. These findings suggest mosun is cost-effective at a $150,000 willingness-to-pay per QALY.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: